EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Cost Effectiveness Analysis Trastuzumab Deruxtecan Versus Trastuzumab Emtansine Pada Pasien Kanker Payudara Metastatik Her2-Positif: Systematic Review

Juan Balapradhana Santoso

International Journal of Health Engineering and Technology · 25.03.2026 · 4 (6)

DOI: 10.55227/ijhet.v4i6.649 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Health Engineering and Technology, online erschienen am 25.03.2026. Verfasst von Juan Balapradhana Santoso. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2-positive breast cancer is one of the subtypes of breast cancer with a poor prognosis and a strong need for effective targeted therapies. Trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) are two antibody-drug conjugates (ADCs) used as second-line treatments for patients with this condition. To evaluate the cost-effectiveness between T-DXd and T- DM1 through a systematic review of relevant literature. Literature search was conducted using Scopus, PubMed, Science Direct, and Google Scholar databases with the keywords “cost effectiveness analysis” AND “metastatic breast cancer” OR “HER2-positive breast cancer” AND “trastuzumab deruxtecan” AND “trastuzumab emtansine”. A total of 521 articles were identified, but only 4 met the inclusion criteria. T-DXd was considered more cost-effective in high- income countries such as the United States (ICER as low as $13,342/QALY) and Finland (ICER approximately €55,360/QALY), but not in China, where the ICER reached $186,017/QALY,

Zitieren

APA

Santoso, J. B. (2026). Cost Effectiveness Analysis Trastuzumab Deruxtecan Versus Trastuzumab Emtansine Pada Pasien Kanker Payudara Metastatik Her2-Positif: Systematic Review. International Journal of Health Engineering and Technology, 4(6). https://doi.org/10.55227/ijhet.v4i6.649

Vancouver

Santoso JB. Cost Effectiveness Analysis Trastuzumab Deruxtecan Versus Trastuzumab Emtansine Pada Pasien Kanker Payudara Metastatik Her2-Positif: Systematic Review. International Journal of Health Engineering and Technology. 2026;4(6). doi:10.55227/ijhet.v4i6.649

BibTeX
@article{Santoso2026,
  author = {Santoso, Juan Balapradhana},
  title = {Cost Effectiveness Analysis Trastuzumab Deruxtecan Versus Trastuzumab Emtansine Pada Pasien Kanker Payudara Metastatik Her2-Positif: Systematic Review},
  journal = {International Journal of Health Engineering and Technology},
  year = {2026},
  volume = {4},
  number = {6},
  doi = {10.55227/ijhet.v4i6.649}
}
Kostenlos starten →